Skip to main content
Archives of Disease in Childhood logoLink to Archives of Disease in Childhood
. 2001 Mar;84(3):227–229. doi: 10.1136/adc.84.3.227

Idiopathic thrombocytopenic purpura and MMR vaccine

E Miller 1, P Waight 1, C Farrington 1, N Andrews 1, J Stowe 1, B Taylor 1
PMCID: PMC1718684  PMID: 11207170

Abstract

A CAUSAL ASSOCIATION BETWEEN MEASLES—mumps-rubella (MMR) vaccine and idiopathic thrombocytopenic purpura (ITP) was confirmed using immunisation/hospital admission record linkage. The absolute risk within six weeks of immunisation was 1 in 22 300 doses, with two of every three cases occurring in the six week post-immunisation period being caused by MMR. Children with ITP before MMR had no vaccine associated recurrences.



Full Text

The Full Text of this article is available as a PDF (73.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Begg N. T., Gill O. N., White J. M. COVER (cover of vaccination evaluated rapidly): description of the England and Wales scheme. Public Health. 1989 Mar;103(2):81–89. doi: 10.1016/s0033-3506(89)80021-6. [DOI] [PubMed] [Google Scholar]
  2. Böttiger M., Christenson B., Romanus V., Taranger J., Strandell A. Swedish experience of two dose vaccination programme aiming at eliminating measles, mumps, and rubella. Br Med J (Clin Res Ed) 1987 Nov 14;295(6608):1264–1267. doi: 10.1136/bmj.295.6608.1264. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Cohn J. Thrombocytopenia in childhood: an evaluation of 433 patients. Scand J Haematol. 1976 Mar;16(3):226–240. doi: 10.1111/j.1600-0609.1976.tb01142.x. [DOI] [PubMed] [Google Scholar]
  4. Farrington C. P. Relative incidence estimation from case series for vaccine safety evaluation. Biometrics. 1995 Mar;51(1):228–235. [PubMed] [Google Scholar]
  5. Farrington P., Pugh S., Colville A., Flower A., Nash J., Morgan-Capner P., Rush M., Miller E. A new method for active surveillance of adverse events from diphtheria/tetanus/pertussis and measles/mumps/rubella vaccines. Lancet. 1995 Mar 4;345(8949):567–569. doi: 10.1016/s0140-6736(95)90471-9. [DOI] [PubMed] [Google Scholar]
  6. Neiderud J. Thrombocytopenic purpura after a combined vaccine against morbilli, parotitis and rubella. Acta Paediatr Scand. 1983 Jul;72(4):613–614. doi: 10.1111/j.1651-2227.1983.tb09780.x. [DOI] [PubMed] [Google Scholar]
  7. Nieminen U., Peltola H., Syrjälä M. T., Mäkipernaa A., Kekomäki R. Acute thrombocytopenic purpura following measles, mumps and rubella vaccination. A report on 23 patients. Acta Paediatr. 1993 Mar;82(3):267–270. doi: 10.1111/j.1651-2227.1993.tb12657.x. [DOI] [PubMed] [Google Scholar]
  8. Oski F. A., Naiman J. L. Effect of live measles vaccine on the platelet count. N Engl J Med. 1966 Aug 18;275(7):352–356. doi: 10.1056/NEJM196608182750703. [DOI] [PubMed] [Google Scholar]
  9. Vlacha V., Forman E. N., Miron D., Peter G. Recurrent thrombocytopenic purpura after repeated measles-mumps-rubella vaccination. Pediatrics. 1996 May;97(5):738–739. [PubMed] [Google Scholar]

Articles from Archives of Disease in Childhood are provided here courtesy of BMJ Publishing Group

RESOURCES